Clinical trials: Chronic Leukaemia
Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow…
- Conditions
- Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
- Trial name
- NCT01928537
- Testing
- rigosertib sodium
- Where
- 35 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Traws Pharma, Inc.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Chronic Myeloid Leukemia in Chronic Phase
Managed Access Programs for ABL001, Asciminib
The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib
- Trial name
- NCT04360005
- Testing
- Asciminib
- Sponsor
- Novartis Pharmaceuticals
CLL/SLL
Global Trial in APG2575 for Patients With CLL/SLL
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK…
- Trial name
- NCT06104566
- Testing
- lisaftoclax +BTK inhibitor, BTK inhibitor
- Where
- 135 sites in United States, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03037645
- Testing
- SNS-062
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Sunesis Pharmaceuticals
Chronic Lymphocytic Leukemia
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
- Trial name
- NORMA (NCT02110394)
- Testing
- bendamustine, rituximab
- Where
- 34 sites in Russia
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Europe B.V.
Lymphoma, B-Cell, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies.
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03162536
- Testing
- Nemtabrutinib
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Chronic Myeloid Leukemia
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT00574873
- Testing
- Bosutinib, imatinib
- Where
- 165 sites in United States, Argentina and 27 more
- Volunteers
- 502 people
- Sponsor
- Pfizer
Hypogammaglobulinemia, Bacterial Infections
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in…
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
- Trial name
- EXCELL (NCT05645107)
- Testing
- Xembify
- Where
- 62 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 386 people
- Sponsor
- Grifols Therapeutics LLC
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL.
- Trial name
- NCT02500407
- Testing
- BTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 713 people
- Sponsor
- Genentech, Inc.
Chronic Myeloid Leukemia - Accelerated Phase
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in accelerated phase (CML-AP) harboring T315I mutation.
- Trial name
- NCT03883100
- Testing
- HQP1351
- Where
- 9 sites in China
- Volunteers
- 23 people
- Sponsor
- Ascentage Pharma Group Inc.
Lymphocytic Leukemia, Chronic
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics as well as the preliminary efficacy of venetoclax (GDC-0199; ABT-199) administered in combination with obinutuzumab to participants…
- Trial name
- NCT01685892
- Testing
- Obinutuzumab, Venetoclax
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Genentech, Inc.
CLL
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
The goal of CICERO is to investigate the clinical outcome with a particular focus on prospective data on safety using acalabrutinib (+/- obinutuzumab) in CLL patients receiving co-medication with DOACs (edoxaban, rivaroxaban…
- Trial name
- CICERO (NCT05517265)
- Testing
- Calquence
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- iOMEDICO AG
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
This study will assess the efficacy, safety and pharmacodynamic markers of the study drug, A6, in patients with CLL and small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, SLL
- Trial name
- NCT02046928
- Testing
- A6
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ångstrom Pharmaceuticals
Malignant Solid Tumour, Ovarian Cancer
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase…
- Conditions
- Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma
- Trial name
- NCT01618136
- Testing
- E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
- Trial name
- NCT02477696
- Testing
- Acalabrutinib, Ibrutinib
- Where
- 130 sites in United States, Australia and 13 more
- Volunteers
- 533 people
- Sponsor
- Acerta Pharma BV
Chronic Myelogenous Leukemia
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had…
- Trial name
- NCT05434312
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Myelodysplastic Syndrome, Myelofibrosis
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
The purpose of this study is to assess the bioequivalence of subcutaneous Vidaza® and subcutaneous Luitpold Azacitidine pharmacokinetics and to assess the comparative safety of subcutaneous Vidaza® versus subcutaneous Luitpold…
- Conditions
- Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT01290302
- Testing
- Luitpold Azacitidine, Vidaza®
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- American Regent, Inc.
Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Ph1 Positive CML
- Trial name
- NCT01159028
- Testing
- BP1001, BP1001 in combination with LDAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bio-Path Holdings, Inc.
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL)
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- RUBIN (NCT06043011)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,950 people
- Sponsor
- iOMEDICO AG